Adalimumab-Associated Hemorrhagic Pericarditis

Rohit Vyas¹, Firas A Adeel¹, Taha Sheikh¹, Mubbasher Syed^{1

2}, Nezam Altorok^{1

3}

Affiliations

¹ Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH.
² Division of Cardiology, Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH.
³ Division of Rheumatology and Immunology, Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH.

Rohit Vyas et al. Am J Ther. 2020 Nov/Dec.

. 2020 Nov/Dec;27(6):e630-e632.

doi: 10.1097/MJT.0000000000001019.

Rohit Vyas¹, Firas A Adeel¹, Taha Sheikh¹, Mubbasher Syed^{1

2}, Nezam Altorok^{1

3}

¹ Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH.
² Division of Cardiology, Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH.
³ Division of Rheumatology and Immunology, Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH.

No abstract available

References

1. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157.
1. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390.
1. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289.
1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
1. Ozkan H, Cetinkaya AS, Yildiz T, et al. A rare side effect due to TNF-alpha blocking agent: acute pleuropericarditis with adalimumab. Case Rep Rheumatol. 2013;2013:985914.